When it comes to which brands spent the most on doctor payments, 2014 crowned a new king--and that's diabetes drug Bydureon.
With big money to be made, drugmakers have responded to the global rise in Type 2 diabetes with a host of new classes of treatments that work in different ways. And while that is generally a good thing, the full range of adverse effects of all of these new drugs can't be known until they have been on the market for awhile, and some will fare better than others, a new report states.
For most biotechs, the huge cost of a late-stage diabetes drug program is enough to shut down any discussion about pushing through alone to an approval. Intarcia, though, says it now has the money needed to do just that for new technology billed as a prospective game-changer for one of the world's most prevalent diseases.
AstraZeneca won U.S. approval of its Bydureon pen for once-weekly treatment of Type 2 diabetes. The pen will be the first of its kind to hit the market. The prefilled, single-use pen injector delivers microspheres that house exenatide, which is slowly released for better glycemic control.
The vials are being retrieved from the U.K., Germany, Romania, the Netherlands, Ireland, Sweden, Finland and Spain, according to BMS spokesman Ken Dominski. The recall was issued because of concerns the vials in the affected batches had not been fully filled.
As goes Eliquis, so goes Bristol-Myers Squibb. That's true this quarter anyway, with the company cutting its full-year revenue and earnings forecasts at the same time it announces remarkably weak sales of its new anticoagulant drug.
When can a drugmaker beat earnings expectations and project a 10% boost in profits for the year and still end up disappointing investors? When that drugmaker is Novo Nordisk, the world's largest insulin maker, focused on a rapidly growing treatment area with investors expecting more, more, more.
Let's face it: When it comes to new drug approvals, projected blockbuster revenue is one of the sexiest aspects of the story. So when Biogen Idec's new Tecfidera was approved for multiple sclerosis, the main competition was seen in bidding up what the drug is likely to bring in for the Boston-based biotech. And the numbers soared to full mega-blockbuster status.
Bristol-Myers Squibb ($BMY) and AstraZeneca ($AZN) dispatching legions of sales reps to tout Byetta and Bydureon? Bring it on, says Novo Nordisk's ($NVO) Mads Krogsgaard Thomsen. The Danish company's chief scientific officer told Bloomberg that more talk about that class of diabetes drugs will help Novo, too.
Novo Nordisk isn't worried about Bydureon. That's what the company said as it announced second-quarter results last month. Now, CFO Jesper Brandgaard explains why, in an interview with Investor's Business Daily.